Fig. 2: RMRP knockdown curbed cell proliferation, facilitated cell apoptosis, and reduced TMZ resistance in glioma cells.

A U251 and LN229 cells were transfected with si-NC, si-RMRP#1, si-RMRP#2, or si-RMRP#3. Forty-eight hours later, RMRP level was examined through RT-qPCR assay (n = 3). B Cell proliferative ability was estimated through CCK-8 assay in U251 and LN229 cells transfected with si-NC or si-RMRP#3 at 0, 24, 48, 72 h post-plating (n = 3). C Cell apoptotic rate was determined by flow cytometry in U251 and LN229 cells transfected with si-NC or si-RMRP#3 at 48 h after transfection (n = 3). D U251, LN229, U251/TMZ, and LN229/TMZ cells were treated with different doses of TMZ for 24 h, followed by the measurement of TMZ IC50 values via CCK-8 assay (n = 3). E and F U251, LN229, U251/TMZ, and LN229/TMZ cells were transfected with si-NC or si-RMRP#3. Transfected cells were seeded into 96-well plates for 24 h and then treated with different concentrations of TMZ for an additional 24 h. Next, the cell survival rate was determined through the CCK-8 assay (n = 3). *P < 0.05. **P < 0.01. ***P < 0.001.